Zepbound’s approval for moderate-to-severe obstructive sleep apnea in adults with obesity created a route to Medicare Part D coverage that did not exist when the drug was approved for weight management alone. Coverage is not automatic — your plan has to include it for that indication, and you need the sleep apnea diagnosis documented.
This is one part of getting a GLP-1 covered. For the full picture, see GLP-1 Insurance Coverage: The Complete Guide.
The same mechanism, a different condition
Part D excludes drugs used for weight loss. That exclusion blocked Zepbound entirely while weight management was its only approved use.
Obstructive sleep apnea is not weight loss. When Zepbound gained approval for treating moderate-to-severe OSA in adults with obesity, it acquired an indication that sits outside the exclusion — the same structural move that opened a path for Wegovy through cardiovascular risk reduction.
The result is that two people can be prescribed the identical drug at the identical dose, and one gets coverage while the other does not, entirely because of what is written in the diagnosis field.
What you need in your record
A documented diagnosis of moderate-to-severe obstructive sleep apnea. In practice this means a sleep study — either an in-lab polysomnogram or a home sleep apnea test — with results establishing severity. A clinical suspicion of sleep apnea is not enough; the plan will want the objective result.
Obesity documented alongside it.
And a plan that has chosen to cover Zepbound for the OSA indication.
Expect prior authorization, and expect the reviewer to look for the sleep study.
If you have never had a sleep study
Untreated sleep apnea is common and frequently undiagnosed, particularly in people with obesity. If you snore heavily, wake unrefreshed, have witnessed breathing pauses, or fall asleep during the day, raising it with your clinician is worthwhile on its own health merits, independent of any medication question.
That said, pursue the sleep study because you may have sleep apnea, not because you want a prescription covered. A study you push for in order to unlock coverage may come back negative, and the honest reason for testing is the better one.
What this does not change
If you have obesity without sleep apnea and without cardiovascular disease, the statutory exclusion still applies and Zepbound is not covered under Part D for weight management. That has not changed.
The sleep study is what carries the request, and GLP-1s for sleep apnea covers the clinical side. If you have cardiovascular disease instead, the Part D route through cardiovascular risk reduction may apply.
Frequently asked questions
Does mild sleep apnea qualify?
The indication specifies moderate-to-severe. Mild OSA generally falls outside it.
I use a CPAP. Does that affect coverage?
Using CPAP does not disqualify you. Some plans may ask about CPAP tolerance or adherence as part of the review. Do not stop using a prescribed CPAP without discussing it with your clinician.
Will Medicare pay for the sleep study?
Sleep studies are generally covered when clinically indicated, subject to standard Medicare rules. Confirm with your plan.
Can I get a home sleep test instead of a lab study?
Often yes, and home testing is widely used. Your clinician will judge which is appropriate for your situation.
Is Mounjaro covered for sleep apnea?
Mounjaro and Zepbound contain the same active ingredient but carry different approved indications. Coverage follows the indication on the label, so this is worth checking specifically with your plan.
What if my plan says no?
Part D has a formal appeals process. If the plan simply has not added the drug to its formulary, a formulary exception request is the mechanism, and your prescriber files it.
Sources
- FDA Prescribing Information, Zepbound (tirzepatide) injection — accessdata.fda.gov
- Social Security Act §1860D-2(e)(2) — ssa.gov
- Medicare coverage of sleep studies — medicare.gov